Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SarCNU in Recurrent Malignant Glioma
NCT00036660Phase 2Completed
- Sponsor
- Canadian Cancer Trials Group
- Start
- Jan 2002
- Primary completion
- Apr 2003
- Modality
- DNA Intercalators/Alkylators
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sarmustine in malignant glioma, sponsored by Canadian Cancer Trials Group. Primary endpoint: Objective Response Rate. Started Jan 2002; status: completed.
02
Drugs
sarmustine
03
Conditions
malignant glioma
Beyond the preview
Go deeper on NCT00036660.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00036660.